Close Menu
Daily Guardian
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
What's On

Prophecy Launches AI Data Prep Tools to Close the Gap Between AI Investment and AI Results

September 8, 2026

From Smart Massage to Proactive Wellness: SKG Expands Its Wearable Health Portfolio at IFA 2026

September 8, 2026

Xiaomi’s wide foldable promises more power than Samsung’s

September 8, 2026

Purna Pharmaceuticals Strengthens Leadership Team With Appointment of Industry Veterans

September 8, 2026

Cytospire Therapeutics Appoints Highly Experienced Immuno-Oncology Leader, Sumeet Ambarkhane, M.D., as Chief Medical Officer

September 8, 2026
Facebook X (Twitter) Instagram
Finance Pro
Facebook X (Twitter) Instagram
Daily Guardian
Subscribe
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
Daily Guardian
Home » Obagi Medical Introduces New Lip Therapy Protocol Designed to Resurface, Replenish, and Protect
Press Release

Obagi Medical Introduces New Lip Therapy Protocol Designed to Resurface, Replenish, and Protect

By News RoomFebruary 3, 20264 Mins Read
Obagi Medical Introduces New Lip Therapy Protocol Designed to Resurface, Replenish, and Protect
Share
Facebook Twitter LinkedIn Pinterest Email

NEW YORK, Feb. 03, 2026 (GLOBE NEWSWIRE) — Obagi Medical (“Obagi”), a leader in advanced skincare innovation, the originator of medical-grade skincare and part of Waldencast plc (NASDAQ: WALD) (“Waldencast” or the “Company”), continues its commitment to advanced skin science with the launch of two new lip innovations designed to work together as a targeted treatment protocol: Obagi Lip Therapy AHA + PHA Smoothing Micro-Peel and Obagi Lip Therapy Soothe & Protect Lip Treatment SPF 30.

Building on the brand’s legacy of clinically backed solutions for skin health and rejuvenation, the new Lip Therapy protocol brings Obagi’s expertise to one of the most delicate areas of the face. Designed for nightly rejuvenation and daily protection, the two-step regimen gently resurfaces the lips while restoring hydration, improving texture, and defending against environmental stressors, including the sun’s UV rays.

“This exciting new launch reflects Obagi’s long-standing approach to skincare innovation,” said Justin Giouzepis, Chief Marketing Officer. “Thoughtful formulation and clinical validation come together in a dermatologist-tested lip protocol that delivers visible smoothing while remaining gentle enough for everyday use.”

The Lip Therapy AHA + PHA Smoothing Micro-Peel is a gentle no-scrub, chemical exfoliating treatment formulated with 3 resurfacing acids: Glycolic Acid, Lactic Acid, and Gluconolactone to resurface and smooth the delicate lip surface. Hyaluronic Acid, a multi-molecular glycerin system, and Argan Oil help lock in moisture and support a softer, smoother, more youthful-looking appearance. Designed as the first step in the regimen, the Micro-Peel visibly smooths texture and can help enhance the performance of subsequent treatments.

Following resurfacing, Soothe & Protect Lip Treatment SPF 30 delivers daily hydration, comfort, and broad-spectrum sun protection. Formulated with a plumping peptide complex, Calendula, Hyaluronic Acid, and Vitamin E, the treatment visibly smooths fine lines while supporting the lip barrier and protecting against UVA and UVB exposure. Its comforting, replenishing formula makes it ideal for everyday use.

In consumer perception testing, when used as part of the complete protocol, the vast majority of users reported their lips looked and felt smoother, plumper, and more replenished immediately after application, with continued improvements in hydration, fine lines, and overall lip appearance in just two weeks.1

“Lips are uniquely vulnerable to environmental damage and dehydration, especially following in-office treatments or the application of wrong topical products,” said Dr. Suzan Obagi, Chief Medical Director. “This two-step protocol addresses both rejuvenation and protection, helping patients maintain smoother, healthier-looking lips with clinically thoughtful ingredients they can trust.”

Together, the Lip Therapy AHA + PHA Smoothing Micro-Peel and Soothe & Protect Lip Treatment SPF 30 reinforce Obagi Medical’s philosophy that skin health is a long-term investment, extending targeted, professional-grade care to deliver visible, science-backed results where they matter most.

Lip Therapy AHA + PHA Smoothing Micro-Peel ($55) and Soothe & Protect Lip Treatment SPF 30 ($40) are now available through partnering professional channels. They will be available for customers to purchase on Obagi.com beginning February 3rd

*Consumer perception study results on file. Results may vary.
1. Data on file at Obagi Cosmeceuticals LLC. Results may vary.
2. Among the Top 10 Professional Skin Care Brands in the U.S., According to Kline’s 2024 Global Professional Skin Care Series (China, Europe and the U.S.)

About Obagi Medical
Obagi Medical is an industry-leading, advanced skincare line rooted in research and skin biology, with a legacy of 35+ years of experience. Initially known for its leadership in the treatment of hyperpigmentation with the Obagi Nu-Derm® System, Obagi Medical products are designed to address a variety of skin concerns, including premature aging, photodamage, skin discoloration, acne, and sun damage. As the fastest-growing professional skincare brand in the U.S. in 2024,2 Obagi Medical empowers individuals to achieve healthy, beautiful skin. More information about Obagi Medical is available on the brand’s website, https://www.obagi.com.

About Waldencast plc
Founded by Michel Brousset and Hind Sebti, Waldencast’s ambition is to build a global best-in-class beauty and wellness operating platform by developing, acquiring, accelerating, and scaling conscious, high-growth purpose-driven brands. Waldencast’s vision is fundamentally underpinned by its brand-led business model that ensures proximity to its customers, business agility, and market responsiveness, while maintaining each brand’s distinct DNA. The first step in realizing its vision was the Business Combination. As part of the Waldencast platform, its brands will benefit from the operational scale of a multi-brand platform; the expertise in managing global beauty brands at scale; a balanced portfolio to mitigate category fluctuations; asset light efficiency; and the market responsiveness and speed of entrepreneurial indie brands. For more information please visit: https://ir.waldencast.com.

Media Contact:
[email protected]

Source: Waldencast plc

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/424b9e84-977f-45a5-bb68-c9e06e9d6e29

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

Keep Reading

Prophecy Launches AI Data Prep Tools to Close the Gap Between AI Investment and AI Results

From Smart Massage to Proactive Wellness: SKG Expands Its Wearable Health Portfolio at IFA 2026

Purna Pharmaceuticals Strengthens Leadership Team With Appointment of Industry Veterans

Cytospire Therapeutics Appoints Highly Experienced Immuno-Oncology Leader, Sumeet Ambarkhane, M.D., as Chief Medical Officer

Pragmatic Semiconductor Appoints Dr. Paul James as Executive Vice President Manufacturing & Operations

Latest Crypto News: Apeing’s Crypto Presale Set to Go Live in Less Than 24 Hours as Ethereum Tests $2,520 

Sigma Announces New 85mm F1.2 Art, 20-60mm F 2.8-4 Contemporary Lenses; YouTube First Look Video and More Info at B&H

Consecutive Profitable Quarters in Second Half of Fiscal 2026

HKC, KOORUI and ANTGAMER Earn Five Honors for Display Innovation at IFA 2026

Editors Picks

From Smart Massage to Proactive Wellness: SKG Expands Its Wearable Health Portfolio at IFA 2026

September 8, 2026

Xiaomi’s wide foldable promises more power than Samsung’s

September 8, 2026

Purna Pharmaceuticals Strengthens Leadership Team With Appointment of Industry Veterans

September 8, 2026

Cytospire Therapeutics Appoints Highly Experienced Immuno-Oncology Leader, Sumeet Ambarkhane, M.D., as Chief Medical Officer

September 8, 2026

Latest News

Pragmatic Semiconductor Appoints Dr. Paul James as Executive Vice President Manufacturing & Operations

September 8, 2026

Latest Crypto News: Apeing’s Crypto Presale Set to Go Live in Less Than 24 Hours as Ethereum Tests $2,520 

September 8, 2026

Sigma Announces New 85mm F1.2 Art, 20-60mm F 2.8-4 Contemporary Lenses; YouTube First Look Video and More Info at B&H

September 8, 2026
Facebook X (Twitter) Pinterest TikTok Instagram
© 2026 Daily Guardian Canada. All Rights Reserved.
  • Privacy Policy
  • Terms
  • Advertise
  • Contact

Type above and press Enter to search. Press Esc to cancel.

Go to mobile version